3 July 2015 - Panther Biotechnology, a company focused on the acquisition and development of small molecule therapeutics for the treatment of Leukemia, Lymphoma and Myeloma, has signed a contract to acquire Alchemia Oncology, a wholly owned subsidiary of Alchemia Limited, an Australian biotechnology company, it was reported on Thursday.Alchemia Oncology Pty Limited has a collection of clinical and pre-clinical oncology assets that include the HyACT Drug Delivery Platform, a range of targeted therapeutics which are aimed to exploit the unique structure and inherent biological properties of Hyaluronic Acid. Drug candidates in the portfolio range from pre-clinical through phase 3.Panther Biotechnology plans to file a new phase three protocol against an open IND with the FDA for HA-Irinotecan in 2015, in addition to advancing the other phase two and phase 1b clinical drug candidates.